|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:atccode
|
M01 AC02
|
|
gptkbp:bioavailability
|
90%
|
|
gptkbp:chemical_formula
|
C13 H10 F2 N2 O3 S
|
|
gptkbp:clinical_trial
|
Phase IV
|
|
gptkbp:contraindication
|
peptic ulcer disease
severe renal impairment
hypersensitivity to aspirin
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:drug_interactions
|
gptkb:methotrexate
gptkb:warfarin
other NSAIDs
|
|
gptkbp:effective_date
|
gptkb:1980
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dolobid
|
|
gptkbp:indication
|
gptkb:rheumatoid_arthritis
musculoskeletal disorders
osteoarthritis
|
|
gptkbp:ingredients
|
gptkb:diflunisal
|
|
gptkbp:legal_status
|
Prescription only
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:mechanism_of_action
|
COX inhibitor
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
dizziness
headache
rash
gastrointestinal upset
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:strength
|
250 mg
|
|
gptkbp:used_for
|
pain relief
inflammation reduction
|
|
gptkbp:bfsParent
|
gptkb:diflunisal
|
|
gptkbp:bfsLayer
|
7
|